Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
All-cause mortality
RCT	322 people with critical limb ischaemia undergoing endovascular or surgical revascularisation	Mortality rate 6 months 13/141 (9%) with lipo-ecraprost (intravenously for 8 weeks) 19/143 (13%) with placebo	P = 0.28 Significantly fewer people in the lipo-ecraprost group adhered to study medication compared with people in the placebo group (see further information on studies for absolute numbers)		Not significant